Who is the manufacturer of ibrutinib/ibrutinib?

Ibrutinib/Ibrutinib is a revolutionary anti-cancer drug that was carefully developed and put into production by Janssen Pharmaceuticals, a well-known American pharmaceutical company. Janssen Pharmaceuticals, as an important pharmaceutical branch of the global healthcare giant Johnson & Johnson, has been committed to providing innovative and efficient treatment solutions to patients around the world.

Ibrutinib has become a high-profile oral targeted drug due to its unique mechanism. It is primarily targeted at patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have had at least one treatment regimen that failed to respond, as well as patients with Waldenstrom's macroglobulinemia (WM) and mantle cell lymphoma (MCL).

The active ingredient of this drugibrutinib can precisely fight against cancerous B lymphocytes. B lymphocytes are an important part of the human immune system, and their normal functions will be destroyed when cancer occurs. By inhibiting an enzyme called Bruton's tyrosine kinase (Btk), ibrutinib effectively blocks the abnormal survival and migration of B lymphocytes, thereby slowing down the progression of cancer.

As a prescription drug, ibrutinib must be used under the guidance of an experienced cancer treatment physician. To meet the needs of different patients, ibrutinib is available in capsules (140 mg) and tablets (140, 280, 420 and 560 mg). For patients with mantle cell lymphoma, the recommended daily dose is 560 mg, while for patients with CLL or WM, 420 mg is typically recommended. Treatment with ibrutinib should be continued as long as the patient's condition continues to improve or remains stable and the side effects of the drug are tolerated.